Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on invested capital (ROIC) high or low?
The return on invested capital (ROIC) of 54.39% is 200% above its 5-year average of -54.18%, near the high end of its 5-year range (-93.89%–56.85%).
As of the fiscal period ended Tuesday, June 30, 2026. 470.14% above its 12-month average of -14.69%.
Trailing-twelve-month return on invested capital at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): 54.39%.
RETURN ON INVESTED CAPITAL (ROIC)
54.39%
RETURN ON INVESTED CAPITAL (ROIC) AVG TTM
-14.69%
RETURN ON INVESTED CAPITAL (ROIC) AVG 3Y
-61.35%
RETURN ON INVESTED CAPITAL (ROIC) AVG 5Y
-54.18%
RETURN ON INVESTED CAPITAL (ROIC) AVG 10Y
-51.38%
RETURN ON INVESTED CAPITAL (ROIC) AVG 15Y
-43.93%
RETURN ON INVESTED CAPITAL (ROIC) AVG 20Y
-42.32%
CURRENT VS TTM AVG
+470.14%
CURRENT VS 3Y AVG
+188.65%
CURRENT VS 5Y AVG
+200.40%
CURRENT VS 10Y AVG
+205.87%
CURRENT VS 15Y AVG
+223.81%
CURRENT VS 20Y AVG
+228.51%
SECTOR MEDIAN · HEALTHCARE
-27.19%
median of 428 covered companies
CURRENT VS SECTOR MEDIAN
+300.04%
vs the sector median at left
Arbutus Biopharma Corp
Market Cap
$922.50M
Return on Invested Capital (ROIC)
54.39%
TTM Avg
-14.69%
3Y Avg
-61.35%
5Y Avg
-54.18%
Market Cap
$921.45M
Return on Invested Capital (ROIC)
4.96%
TTM Avg
4.19%
3Y Avg
3.59%
5Y Avg
3.20%
Market Cap
$915.95M
Return on Invested Capital (ROIC)
11.37%
TTM Avg
4.29%
3Y Avg
-4.73%
5Y Avg
-2.12%
Market Cap
$903.13M
Return on Invested Capital (ROIC)
-25.25%
TTM Avg
-75.69%
3Y Avg
-67.13%
5Y Avg
-61.15%
Market Cap
$943.26M
Return on Invested Capital (ROIC)
-46.54%
TTM Avg
-25.88%
3Y Avg
-39.60%
5Y Avg
-39.60%
Market Cap
$867.60M
Return on Invested Capital (ROIC)
-28.69%
TTM Avg
-21.44%
3Y Avg
-33.52%
5Y Avg
-49.04%
Market Cap
$866.15M
Return on Invested Capital (ROIC)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$985.79M
Return on Invested Capital (ROIC)
-68.64%
TTM Avg
-46.08%
3Y Avg
-28.67%
5Y Avg
-26.80%
Market Cap
$989.05M
Return on Invested Capital (ROIC)
-16.54%
TTM Avg
-24.45%
3Y Avg
-23.43%
5Y Avg
-23.43%
| NAME | MARKET CAP | RETURN ON INVESTED CAPITAL (ROIC) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $922.50M | 54.39% | -14.69% | -61.35% | -54.18% |
| HealthStream, Inc. (HSTM)vs › | $921.45M | 4.96% | 4.19% | 3.59% | 3.20% |
| Bioventus Inc. (BVS)vs › | $915.95M | 11.37% | 4.29% | -4.73% | -2.12% |
| Corvus Pharmaceuticals, Inc. (CRVS)vs › | $903.13M | -25.25% | -75.69% | -67.13% | -61.15% |
| CeriBell, Inc. (CBLL)vs › | $943.26M | -46.54% | -25.88% | -39.60% | -39.60% |
| Monte Rosa Therapeutics, Inc. (GLUE)vs › | $867.60M | -28.69% | -21.44% | -33.52% | -49.04% |
| Apnimed, Inc. (APMD)vs › | $866.15M | N/A | N/A | N/A | N/A |
| Cullinan Therapeutics, Inc. (CGEM)vs › | $985.79M | -68.64% | -46.08% | -28.67% | -26.80% |
| Aktis Oncology, Inc. (AKTS)vs › | $989.05M | -16.54% | -24.45% | -23.43% | -23.43% |
| Beta Bionics, Inc. (BBNX)vs › | $852.55M | -31.17% | -29.64% | -85.48% | -85.48% |
ROIC
54.4%
ROE
59.2%
ROIC = NOPAT / Invested Capital, where NOPAT = Operating Income × (1 − effective tax rate) and Invested Capital = Total Assets − (Current Liabilities − Short-Term Debt)
Return on invested capital measures the after-tax operating return a company earns on the capital invested in the business. TGMCharts computes it from reported statements: trailing-twelve-month operating income after tax, over invested capital at the latest balance sheet — total assets less the non-interest-bearing current liabilities (payables, accruals, deferred revenue) that fund them; short-term debt stays in the capital base. The tax rate is the period's own effective rate (income tax ÷ pretax income), capped at 45%; when pretax income is zero or negative, or the tax line is a net benefit, no tax is deducted — the operating figure is shown untaxed rather than adjusted by an assumed rate. Not shown for banks, insurers or funds.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON INVESTED CAPITAL (ROIC) |
|---|---|
| 2026-06-30 | 54.39% |
| 2026-03-31 | 56.85% |
| 2025-12-31 | -55.08% |
| 2025-09-30 | -59.87% |
| 2025-06-30 | -69.77% |
| 2025-03-31 | -93.89% |
| 2024-12-31 | -65.74% |
| 2024-09-30 | -68.41% |
| 2024-06-30 | -60.37% |
| 2024-03-31 | -61.58% |
| 2023-12-31 | -64.06% |
| 2023-09-30 | -58.63% |
| 2023-06-30 | -50.02% |
| 2023-03-31 | -43.29% |
| 2022-12-31 | -40.17% |
| 2022-09-30 | -36.13% |
| 2022-06-30 | -34.49% |
| 2022-03-31 | -33.59% |
| 2021-12-31 | -37.97% |
| 2021-09-30 | -44.40% |
| 2021-06-30 | -51.88% |
| 2021-03-31 | -43.10% |
| 2020-12-31 | -45.32% |
| 2020-09-30 | -44.03% |
| 2020-06-30 | -143.18% |
| 2020-03-31 | -140.08% |
| 2019-12-31 | -147.40% |
| 2019-09-30 | -136.35% |
| 2019-06-30 | -48.38% |
| 2019-03-31 | -45.13% |
| 2018-12-31 | -41.44% |
| 2018-09-30 | -57.20% |
| 2018-06-30 | -42.79% |
| 2018-03-31 | -42.77% |
| 2017-12-31 | -49.85% |
| 2017-09-30 | -133.03% |
| 2017-06-30 | -129.20% |
| 2017-03-31 | -190.45% |
| 2016-12-31 | -185.29% |
| 2016-09-30 | -48.58% |
| 2016-06-30 | -54.75% |
| 2016-03-31 | -15.07% |
| 2015-12-31 | -14.58% |
| 2015-09-30 | -14.29% |
| 2015-06-30 | -6.55% |
| 2015-03-31 | -5.91% |
| 2014-12-31 | -33.65% |
| 2014-09-30 | -23.37% |
| 2014-06-30 | -18.57% |
| 2014-03-31 | -13.04% |
| 2013-12-31 | -20.50% |
| 2013-09-30 | -52.19% |
| 2013-06-30 | -40.36% |
| 2013-03-31 | -34.73% |
| 2012-12-31 | -30.91% |
| 2012-09-30 | -679.33% |
| 2012-06-30 | -188.14% |
| 2012-03-31 | -148.21% |
| 2011-12-31 | -157.01% |
| 2011-09-30 | -186.14% |
| 2011-06-30 | -104.38% |
| 2011-03-31 | -111.17% |
| 2010-12-31 | -96.85% |
| 2010-09-30 | -30.39% |
| 2010-06-30 | -48.34% |
| 2010-03-31 | -34.64% |
| 2009-12-31 | -24.22% |
| 2009-09-30 | -23.29% |
| 2009-06-30 | -24.25% |
| 2009-03-31 | -34.16% |
| 2008-12-31 | -29.17% |
| 2008-09-30 | -18.26% |
| 2008-06-30 | -7.79% |
| 2008-03-31 | 6.21% |
